Loncar Cancer Immunotherapy ETF (CNCR)

21.31
Delayed Data
As of Nov 15
 +0.3228 / +1.54%
Today’s Change
16.87
Today|||52-Week Range
22.53
+12.92%
Year-to-Date

Investment Objective

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

No recent news for Loncar Cancer Immunotherapy ETF.

Performance

1 month+15.45% 3 years-5.04%
3 months+9.60% 5 years--
1 year+2.82% Since inception-3.37%
Data through 11/16/2019

Quote Details

Previous close$20.99
Open day’s range21.00 – 21.33
Net asset value (NAV)21.33 (11/15/2019)
Daily volume15,114
Average volume (3 months)8,136
Data as of 3:32pm ET, 11/15/2019

Peer Comparisonvs. Health ETFs

 CNCRCategory
Performance 5-yr return--+7.05%
Expense Gross exp ratio0.79%1.24%
Risk 5 year sharpe ratio--0.44
Net assets$32.7M$3.1B
Average market cap$5.2B$40.0B
Average P/E--26.1
Dividend / Share--0.26%

Competitors

VHT Vanguard Health Care Index Fund ETF Shar...
FHLC Fidelity MSCI Health Care Index ETF
IXJ iShares Global Healthcare ETF

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
ZYME Zymeworks Inc6.81%
SGEN Seattle Genetics Inc6.32%
YMAB Y-mAbs Therapeutics, Inc5.79%
AZN AstraZeneca5.04%
BMY Bristol-Myers Squibb5.01%
-- 4.63%
BGNE Beigene Ltd4.50%
MOR MorphoSys AG4.44%
IOVA Iovance Biotherapeutics Inc4.44%
ALLO Allogene Therapeutics Inc4.38%